loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X

List of Revumenib NDC API suppliers/manufacturers & exporters

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 Curia New York, Inc. (1)

filter

01 SNDX-5613 (1)

filter

01 U.S.A (1)

URL Supplier Web Content
SNDX-5613
POWDER (1kg/kg)
BULK INGREDIENT
65392-3402
2023-11-10
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for 2169919-21-3 / Revumenib API manufacturers, exporters & distributors?

Revumenib manufacturers, exporters & distributors 1

99

PharmaCompass offers a list of Revumenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Revumenib manufacturer or Revumenib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Revumenib manufacturer or Revumenib supplier.

PharmaCompass also assists you with knowing the Revumenib API Price utilized in the formulation of products. Revumenib API Price is not always fixed or binding as the Revumenib Price is obtained through a variety of data sources. The Revumenib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Revumenib

Synonyms

Sndx-5613, 2169919-21-3, Lz0m43nnf2, Sndx5613, Sndx-5613 free base, N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-n-propan-2-ylbenzamide

Cas Number

2169919-21-3

Unique Ingredient Identifier (UNII)

LZ0M43NNF2

About Revumenib

Revumenib is an orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.

Revumenib Manufacturers

A Revumenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Revumenib, including repackagers and relabelers. The FDA regulates Revumenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Revumenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Revumenib Suppliers

A Revumenib supplier is an individual or a company that provides Revumenib active pharmaceutical ingredient (API) or Revumenib finished formulations upon request. The Revumenib suppliers may include Revumenib API manufacturers, exporters, distributors and traders.

Revumenib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Revumenib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Revumenib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Revumenib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Revumenib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Revumenib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Revumenib suppliers with NDC on PharmaCompass.

Revumenib Manufacturers | Traders | Suppliers

Revumenib Manufacturers, Traders, Suppliers 1
20

We have 1 companies offering Revumenib

Get in contact with the supplier of your choice:

  1. Curia
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Post Enquiry
POST ENQUIRY